These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 10716967)

  • 1. Association of angiogenesis in lymph node metastases with outcome of breast cancer.
    Guidi AJ; Berry DA; Broadwater G; Perloff M; Norton L; Barcos MP; Hayes DF
    J Natl Cancer Inst; 2000 Mar; 92(6):486-92. PubMed ID: 10716967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunohistochemical study of angiogenesis of axillary lymph node metastasis in human breast carcinoma].
    Wu L; Zhang W; Liu H
    Zhonghua Zhong Liu Za Zhi; 1999 Nov; 21(6):433-5. PubMed ID: 11776619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IV-DSA is a new diagnostic tool for axillary lymph node metastasis in breast cancer patients.
    Watanabe O; Shimizu T; Imamura H; Kinoshita J; Utada Y; Okabe T; Kimura K; Hirano A; Aiba M; Ogawa K
    J Surg Oncol; 2004 Aug; 87(2):75-9. PubMed ID: 15282699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
    Guidi AJ; Berry DA; Broadwater G; Helmchen B; Bleiweiss IJ; Budman DR; Henderson IC; Norton L; Hayes DF
    J Clin Oncol; 2002 Feb; 20(3):732-42. PubMed ID: 11821455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chalkley microvessel but not lymphatic vessel density correlates with axillary lymph node metastasis in primary breast cancers.
    Kanngurn S; Thongsuksai P; Chewatanakornkul S
    Asian Pac J Cancer Prev; 2013; 14(1):583-7. PubMed ID: 23534799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvessels that predict axillary lymph node metastases in patients with breast cancer.
    Nathanson SD; Zarbo RJ; Wachna DL; Spence CA; Andrzejewski TA; Abrams J
    Arch Surg; 2000 May; 135(5):586-93; discussion 593-4. PubMed ID: 10807285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
    Rouzier R; Extra JM; Klijanienko J; Falcou MC; Asselain B; Vincent-Salomon A; Vielh P; Bourstyn E
    J Clin Oncol; 2002 Mar; 20(5):1304-10. PubMed ID: 11870173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
    Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
    Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of contralateral axillary lymph node metastasis from breast cancer: a clinical dilemma.
    Wang W; Yuan P; Wang J; Ma F; Zhang P; Li Q; Xu B
    Tumori; 2014; 100(6):600-4. PubMed ID: 25688492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer.
    Meric F; Mirza NQ; Buzdar AU; Hunt KK; Ames FC; Ross MI; Pollock RE; Newman LA; Feig BW; Strom EA; Buchholz TA; McNeese MD; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 2000 Jul; 7(6):435-40. PubMed ID: 10894139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete axillary lymph node dissection for stage I-II carcinoma of the breast.
    Danforth DN; Findlay PA; McDonald HD; Lippman ME; Reichert CM; d'Angelo T; Gorrell CR; Gerber NL; Lichter AS; Rosenberg SA
    J Clin Oncol; 1986 May; 4(5):655-62. PubMed ID: 3701387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The analysis of CD34 antigen immunoreactivity level in invasive ductal breast cancer with respect to the presence of lymph node metastases.
    Popiela TJ; Sikora J; Klimek M; Basta P; Niemiec T; Dobrogowski J; Kotlarz A; Rudnicka-Sosin L; Dutsch-Wicherek M
    Neuro Endocrinol Lett; 2008 Aug; 29(4):443-6. PubMed ID: 18766141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.